Skip to content
ES
MARKETS / BALCAO / MDNC
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Medinotec Inc. MDNC

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.7M
▲ 6.8% YoY
$794,502
▼ 63.2% YoY
$905,435
▲ 14.8% YoY
In brief

What this company does

We currently generate revenue from two principal sources: (1) internally designed and manufactured proprietary medical devices and (2) distribution of third-party medical products under exclusive or non-exclusive agreements in defined territories. As of February 28, 2026, the Medinotec Group of Companies had 48 employees and independent contractors supporting its operations. The Trachealator received FDA 510(k) clearance in November 2021, permitting the Company to market the product in the United States. The Company designed and developed the Cape Cross range of semi-compliant coronary PTCA catheters.

Written from the business description in Medinotec Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 28 May 2026. Every sentence was checked against that document before publication.

Growth
USD 9.7M
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 9.7 · Net income 0.8
4M8M2022202320242025
Compound annual growth
+113.5%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 11.2% · Net 8.2%
10%20%30%-10%-20%-30%2022202320242025
ROE
FY2025 · ROE 15.9%
20%40%60%-5%-10%-15%2022202320242025
Gross margin52.7%
Operating margin11.2%
Net margin8.2%
Return on assets11.7%
EBITDAUSD 1.2M

Each USD of equity produced 16 cents of profit this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $
FY2025 · FCF 905435.0
400000800000-200000-4000002022202320242025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 6.8M
EquityUSD 5.7M
CashUSD 2.8M
Current ratio5.83×

Equity funds 84% of total assets.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022
Revenue $B0.00.00.00.0
Operating income $B0.00.00.0−0.0
EBITDA $B0.00.00.0−0.0
Income tax $B−0.0−0.0−0.00.0
Net income $B0.00.0−0.0−0.0
Free cash flow $B0.00.00.0−0.0
EPS, diluted $0.070.18−0.03−0.03
Dividend / sh $····
Payout %····
ROE %15.967.1−17.1−13.8
Shares out B0.010.010.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 2 divergences in 16 reconciliationsAUDITED

Reconciled in 2 of 19 fiscal years. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 79 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures2 divergent
ActivitySurgical & Medical Instruments & Apparatus
Listed onOTC market
Incorporated inNevada
Fiscal year endsFebruary 28
SEC categoryemerging growth company, smaller reporting company
Data on record since2022

Share this section

Download image